CD8A and neoplasm: Despite the difference in the molecular weights of IL12 and NHS-muIL12, the latter demonstrated a tumor-retention effect superior to recombinant muIL-12 [89], which enhanced and prolonged cytotoxic effector functions of CD8+ T cells at the tumor site.